VTEX Margin Gains Impress, But Weak Growth Keeps The Stock On Hold

What happened

VTEX continues to impress with margin expansion—non-GAAP subscription gross margin hit 80.2% in Q3 2025—yet topline growth languishes as weak Brazilian and Argentine demand drags same-store sales and the take-rate slipped to 1.21% in Q2 2025. Management is pushing global expansion and new products like VTEX Ads and AI capabilities, but near-term revenue remains overwhelmingly tied to volatile Latin American markets. The company’s debt-free balance sheet and $40 million buyback authorization offer a safety net, but the stock’s rich valuation at 34.7x P/E leaves no room for stagnation. The market has priced in a “growth visibility problem,” and recent analyst downgrades underscore the need for tangible re-acceleration. Until VTEX delivers two consecutive quarters of FX-neutral subscription growth above 10% and stabilizes its take-rate, the stock remains a WAIT.

Implication

VTEX’s operational discipline has driven notable margin expansion, with subscription gross margins now above 80%, yet this is overshadowed by stagnant revenue growth from its core Latin American markets. The company’s growth visibility remains clouded by Brazil’s economic weakness and Argentina’s demand softness, compounded by a declining take-rate that pressures monetization. Management’s focus on global expansion and new products like VTEX Ads offers potential upside, but these initiatives have yet to materially shift the revenue mix or offset regional headwinds. The $40 million buyback program and debt-free balance sheet provide downside support, but the elevated valuation multiples demand a return to sustainable growth. We maintain our WAIT rating until consecutive quarters demonstrate FX-neutral subscription growth above 10% and take-rate stabilization, which would signal that the growth story is back on track.

Thesis delta

The new Seeking Alpha article reinforces our existing thesis without altering the fundamental outlook. It highlights the same tension between improving margins and weak growth, confirming that the near-term investment case hinges on proof of re-acceleration. No change to our WAIT rating, conviction, or price targets.